SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients

Type 2 diabetes mellitus (T2DM) is the cause of the development of diabetic nephropathy — a complication that determines the high degree of disability and mortality of such patients. Until recently, approaches to normalizing glucose levels did not have a significant possibility of influencing the ou...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vladimir V Salukhov, Yurii Sh. Khalimov, Sergey B. Shustov, Sergey I. Popov
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2021
Materias:	type 2 diabetes mellitus diabetic nephropathy end-stage renal disease albuminuria glomerular filtration rate nephroprotection type 2 sodium glucose cotransporter inhibitors Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/5c7f859deb01455f8bc09e299148dcde
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5c7f859deb01455f8bc09e299148dcde
record_format	dspace
spelling	oai:doaj.org-article:5c7f859deb01455f8bc09e299148dcde2021-11-14T09:00:23ZSGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients2072-03512072-037810.14341/DM12123https://doaj.org/article/5c7f859deb01455f8bc09e299148dcde2021-01-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/12123https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Type 2 diabetes mellitus (T2DM) is the cause of the development of diabetic nephropathy — a complication that determines the high degree of disability and mortality of such patients. Until recently, approaches to normalizing glucose levels did not have a significant possibility of influencing the outcome of kidney damage in diabetes. Type 2 sodium glucose cotransporter inhibitors (SGLT2) are a new class of glucose-lowering drugs that improve glycemic control due to an insulin-independent mechanism of action associated with increased urinary glucose excretion. The review provides an analysis of the results of studies on the assessment of nephroprotective actions — one of the pleiotropic actions of this drugs group. These materials show the properties of SGLT2 inhibitors to reduce the risk of developing and the progression of albuminuria, to save glomerular filtration rate, to reduce the frequency of end-stage renal disease and the need for renal replacement therapy in patients with T2DM. The article gives and analyzes the currently existing hypotheses of the mechanism of action of these glucose-lowering drugs. The risk of the most common renal complications with the use of SGLT2 inhibitors is considered. The practical aspects of the use of SGLT2 inhibitors in modern algorithms for the care of patients with T2DM are indicated, as well as the prospects for new randomized clinical trials.Vladimir V SalukhovYurii Sh. KhalimovSergey B. ShustovSergey I. PopovEndocrinology Research Centrearticletype 2 diabetes mellitusdiabetic nephropathyend-stage renal diseasealbuminuriaglomerular filtration ratenephroprotectiontype 2 sodium glucose cotransporter inhibitorsNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 23, Iss 5, Pp 475-491 (2021)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	type 2 diabetes mellitus diabetic nephropathy end-stage renal disease albuminuria glomerular filtration rate nephroprotection type 2 sodium glucose cotransporter inhibitors Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	type 2 diabetes mellitus diabetic nephropathy end-stage renal disease albuminuria glomerular filtration rate nephroprotection type 2 sodium glucose cotransporter inhibitors Nutritional diseases. Deficiency diseases RC620-627 Vladimir V Salukhov Yurii Sh. Khalimov Sergey B. Shustov Sergey I. Popov SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
description	Type 2 diabetes mellitus (T2DM) is the cause of the development of diabetic nephropathy — a complication that determines the high degree of disability and mortality of such patients. Until recently, approaches to normalizing glucose levels did not have a significant possibility of influencing the outcome of kidney damage in diabetes. Type 2 sodium glucose cotransporter inhibitors (SGLT2) are a new class of glucose-lowering drugs that improve glycemic control due to an insulin-independent mechanism of action associated with increased urinary glucose excretion. The review provides an analysis of the results of studies on the assessment of nephroprotective actions — one of the pleiotropic actions of this drugs group. These materials show the properties of SGLT2 inhibitors to reduce the risk of developing and the progression of albuminuria, to save glomerular filtration rate, to reduce the frequency of end-stage renal disease and the need for renal replacement therapy in patients with T2DM. The article gives and analyzes the currently existing hypotheses of the mechanism of action of these glucose-lowering drugs. The risk of the most common renal complications with the use of SGLT2 inhibitors is considered. The practical aspects of the use of SGLT2 inhibitors in modern algorithms for the care of patients with T2DM are indicated, as well as the prospects for new randomized clinical trials.
format	article
author	Vladimir V Salukhov Yurii Sh. Khalimov Sergey B. Shustov Sergey I. Popov
author_facet	Vladimir V Salukhov Yurii Sh. Khalimov Sergey B. Shustov Sergey I. Popov
author_sort	Vladimir V Salukhov
title	SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
title_short	SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
title_full	SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
title_fullStr	SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
title_full_unstemmed	SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
title_sort	sglt2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
publisher	Endocrinology Research Centre
publishDate	2021
url	https://doaj.org/article/5c7f859deb01455f8bc09e299148dcde
work_keys_str_mv	AT vladimirvsalukhov sglt2inhibitorsandkidneysmechanismsandmaineffectsindiabetesmellituspatients AT yuriishkhalimov sglt2inhibitorsandkidneysmechanismsandmaineffectsindiabetesmellituspatients AT sergeybshustov sglt2inhibitorsandkidneysmechanismsandmaineffectsindiabetesmellituspatients AT sergeyipopov sglt2inhibitorsandkidneysmechanismsandmaineffectsindiabetesmellituspatients
_version_	1718429465982271488

SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients

Ejemplares similares